QUANTITATIVE IMMUNOCYTOCHEMISTRY ASSAY

Abstract: An internal control or standard is provided for the direct quantitative assay by immunocytochemistry of target molecules in tissue specimens and the like. The control is subjected to the same conditions including immunostaining as the tissue specimen. Optical density of the control and the specimen after staining is compared, preferably by a cell analysis computer system.

Description: QUANTITATIVE IMMUNOCYTOCHEMISTRY ASSAY This application is a continuation of United States application Serial No. 07/412,450 filed 26 September 1989, which is still pending. This invention relates to the direct quantitative determination by immunocytochemistry of target molecules in tissue specimens. BACKGROUND OF THE INVENTION Assays to determine the presence or absence of target molecules in tissue specimens typically entail the running of an appropriate biochemical test on a tissue homogenate. Assays for estrogen receptor (ER) and progesterone receptor (PR) are of value in predicting tumor response and are routinely done in homogenates of breast cancer. Tissue homogenates for quantitative biochemical assays are based on a variable number of normal cells and cells such as cancer cells which express target molecules. Immunocytochemistry has a theoretical advantage over such biochemical assays in that it directly measures the presence or absence of the target molecules in the relevant cells. To date, however, this advantage has not been realized because current immunocytochemistry is based on a visual estimation of the intensity of the immunostaining reaction product. This procedure has major drawbacks which preclude its use as a precise, reproducible, quantitative assay. Among other things: (1) The various tissue processing steps (fixation time, type of fixative, dehydration, embedding and related procedures) are all responsible for some variation, in particular loss of antigen, which modifies the im unostain signal. These variables are difficult to control as they depend on fixative concentration, temperature, contaminants and, importantly, time. (2) The thickness of the tissue section is difficult to control—an important factor because the signal strength increases as a function of section thickness. (3) The staining procedure will indicate differences in intensity of immunoreactivity depending upon multiple variables, such as antibody concentration, timing, type of chromogen used, and the like. SUMMARY OF THE INVENTION This invention replaces the visual estimation procedure of the prior art with a practical technique for utilizing the capability of immunocytochemistry to measure quantitatively the presence or absence of a target molecule in the cells of a tissue or other specimen. More particularly, the invention provides a control or internal standard containing a known amount of antigen (or other target molecules) to be processed concurrently with the tissue specimen. The control is thus subjected to all of the same conditions as the tissue specimen to be assayed. For example, a decrease of 30% in the availability of an antigen to .be detected will equally affect the control and the specimen under examination. Because the control has cells with a known amount of antigen or other target molecules, a compensating factor can readily be determined, and a quantitative assay of the tissue specimen accomplished. DESCRIPTION OF THE INVENTION The control provided by this invention may be a section or slice of a medium, such as gelatin, agar or any other aqueous embedding medium, having embedded therein cells, such as MCF7 (a known breast cancer cell line which expresses ER and PR) or BT474 (a known cell line which expresses a breast cancer oncogene) , expressing a defined amount of a target molecule. More specifically, cells grown in tissue culture are suspended in the gelatin or other embedding medium which is allowed to solidify by cooling or polymerization. The solidified medium containing the cell suspension is cut into sections or slices of appropriate thickness, e.g., a thickness of from about 2 to about 5 mm. Choice of cell type depends upon the type of antigen or other molecules to be measured. There is a plethora of cells of many types expressing a variety of antigens or other molecules. Transfected cells may be used. Target molecules which may be quantified in a specimen by use of this invention include, for example, proteins expressed by oncogenes, cell growth factors, and any of the various molecules that control cell proliferation. The pathologist receiving, for example, a breast biopsy suspected of containing cancer cells includes a control slice embodying the invention into the cassette to insure that both the tissue sample and the control are concurrently subjected to all ensuing procedures through immunostaining. The optical density of the stained cancer cells in the biopsy sample is compared to that of the cells in the control which acts as an internal standard. Preferably, the comparison is made by use of a computerized cell analysis system, such as a CAS 200 image analyzer (Cell Analysis Systems, Inc., Lombard, Illinois) . EXAMPLE Cells grown in tissue culture (MCF7 and BT474) , known to express a defined amount of the antigens to be measured, were briefly fixed in paraformaldehyde and suspended in a 3% agar solution (Difco, Detroit, Michigan) at 56°C and allowed to gel. Uniform slices, 3 mm thick, were fixed in formaldehyde for periods of time ranging from 4 to 72 hours and processed together into a single paraffin block. The cross-sectional dimensions of the block were about 2 by about 2.5 cm. Sections cut at 5 microns were im unostained for estrogen receptor (ER-ICA, Abbott, Illinois) and cERB-b2 oncoprotein (Triton Bios., Alameda, California) . The intensity of the immunoreactivity was measured for each quantitation of immunocytochemistry gel with a CAS 200 image analyzer. Progressive reduction in the intensity of the immunoreactivity, which correlated with the lengthening of the fixation time was detected with both antigens. Significantly, such reduction was not noticeable by conventional microscopy in the ER-ICA stains.

Claims: HAT IS CLAIMED IS: 1. A control for use in quantitative immunocytochemistry assays which comprises a section of a solidified embedding medium having suspended therein cells which express a defined amount of, a preselected target molecule. 2. A control as defined by claim 1 in which the target molecule is an antigen, a protein expressed by an oncogene, a cell growth factor, a receptor molecule, or a molecule that controls the proliferation of a cell. 3. A control as defined by claim 1 or claim 2 in which the preselected target molecule expressed by said cells embedded in said solidified embedding medium is an antigen. 4. A control as defined by claim 1 or claim 2 in which said antigen is an estrogen receptor or a progesterone receptor. 5. A control for use in the quantitative immunocytochemistry assay of a breast tissue for estrogen and progesterone receptors which comprises a section of solidified agar having embedded therein MCF7 cells which express a defined amount of estrogen receptors and progesterone receptors. 6. An immunocytochemical method for the direct, quantitative determination of the presence or absence of a target molecule in the cells of a tissue specimen which comprises concurrently subjecting said specimen and a control as defined by claim 1 to all of the same processing steps including immunostaining and thereafter comparing the optical density of the stained tissue specimen cells with the optical density of the control cells. * 7. A method as defined by claim 6 in which the comparison of the optical density of the stained tissue specimen cells with the optical density of the stained control cells is made by use of a computerized cell analysis system. 8. A method as defined by claim 6 or claim 7 in which said target molecule is an antigen.

Inventors: BATTIFORA HECTOR A, BATTIFORA, HECTOR, A.
Applicants: HOPE CITY, CITY OF HOPE
Application year: 1990
Main classification: G01N33
IPC codes: G01N33